Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Saturday's Exclusive Story A Fresh IPO That Long-Term Investors Shouldn't IgnoreSubmitted by Jordan Chussler. First Published: 1/14/2026. 
Article Highlights - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them can offer considerable short-term upside potential. They also carry substantial downside risk. But even conservative investors shouldn't dismiss every recent IPO; some newly public stocks may deserve a place in buy-and-hold portfolios. While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies... Discover how to invest in the fund Trump uses to collect this income >> One healthcare company that just went public could fit that profile. Last Year's IPO Success Stories Last year demonstrated why IPOs merit attention—even from investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since its IPO. Short-term traders may have pocketed larger gains—its shares surged almost 359% within 30 days of listing—but longer-term holders have still seen strong returns. Other listings show that IPOs aren't exclusively high-risk bets. The medical products and services provider Medline (NASDAQ: MDLN), which publicly debuted in December 2025, was founded in 1966 and now has a market cap exceeding $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—known for its bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and pays a dividend that currently yields 4.44% (about $1 per share annually), making it an immediate consideration for income investors. After its IPO, with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. These drugs combine radioactive isotopes with a targeting module that seeks out specific cells (for example, cancer cells) to deliver localized doses of radiation, minimizing harm to healthy tissue compared with some conventional treatments. According to industry consultancy Grand View Research, the global nuclear medicine market, estimated at nearly $18 billion in 2024, is forecast to reach nearly $35 billion by 2030—a compound annual growth rate of about 10.16%. Grand View Research also notes that North America accounts for nearly 43% of the market, with the United States as the dominant regional player—an important detail for Boston-based Aktis Oncology. Aktis Oncology's Clinical-Stage Business Wall Street expects biotech IPO activity to rebound in 2026 after funding changes slowed healthcare listings in 2025. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised one of the largest amounts seen recently for a biotech offering. The company raised $318 million in the IPO and now has a market cap of about $3.34 billion. According to the company's prospectus, its executive team includes drug-development, regulatory and commercialization veterans who have helped bring 14 currently FDA-approved products to market. At a technical level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision oncology drugs that use proprietary technology to attack solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not stop it from attracting significant industry backing. Eli Lilly (NYSE: LLY) anchored the IPO and, according to Reuters, purchased $100 million of AKTS shares. That investment builds on a 2024 partnership under which Eli Lilly committed $60 million in cash and an equity investment in Aktis, with potential milestone payments that could exceed $1 billion. The relationship centers on developing tumor-targeting radiopharmaceuticals. The significance of Eli Lilly's backing is considerable. With a market cap of about $1.01 trillion, Lilly is one of Big Pharma's largest companies after reporting a near 109% year-over-year jump in net income from 2023 to 2024. That performance is expected to continue when Eli Lilly reports Q4 and full-year 2025 financials on Feb. 5. Between its equity stake and the recent $100 million in AKTS shares, the maker of Zepbound now has a sizable financial interest in Aktis' success.
| 
